Hematology Times
|
Merck Serono CEO stakes out Boston biotech startupsMay 24, 2013 09:25 AM
Merck Serono CEO Stephan Oschmann has made overtures to biotech entrepreneurs as the pharma group seeks ways to bolster its business after a series of R&D setbacks such as the failure of an experimental oral drug for multiple sclerosis and major layoffs and cutbacks in Geneva, Switzerland. [Read News ...]Pfizer denies knowledge of acquired companies' failures in East German drug trialsMay 24, 2013 09:08 AM
As Bloomberg reports, Germany's Der Spiegel has ferreted more details about drug research in Soviet-era East Germany, where pharma groups tied to some of the biggest names in the industry reportedly benefited from cheap clinical trials before the fall of the Berlin Wall. [Read News ...]Amid deal frenzy, Elan rejects latest buyout bid from Royalty PharmaMay 24, 2013 08:31 AM
Elan's ($ELN) board of directors has rebuffed the most recent acquisition offer from Royalty Pharma, saying that the bid valued at $6.4 billion undervalues the Ireland-based biopharma group and robs investors of the best value for their shares. With its eyes on Elan's prized Tysabri royalty stream, Royalty made the most recent $12.50-per-share offer on Monday. [Read News ...]We're taking Memorial Day offMay 24, 2013 07:35 AMAveo shares shellacked after Astellas drops EU game plan on kidney cancerMay 24, 2013 07:28 AM
Three weeks after an FDA panel overwhelmingly rejected Aveo's bid to gain an approval for its kidney cancer drug tivozanib, the biotech has earned another vote of no confidence--this time from its pharma partner. [Read News ...]Merck marks another failure in elusive hunt for Parkinson's disease drugsMay 24, 2013 07:22 AM
Merck has cut one of most advanced efforts to develop a new therapy for Parkinson's disease. Its Phase III clinical trials of preladenant for the prevalent neurological disorder failed to beat placebo, prompting the U.S. drug giant ($MRK) to halt extension studies of the experimental A2A receptor agonist and abandon plans to file for regulatory approvals for the treatment. [Read News ...]Health centers get $150 million for insurance enrollment helpMay 24, 2013 04:00 AMHHS says the effort is intended to simplify the process of signing up for new insurance options under the Affordable Care Act. [Read News ...] Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: ReportMay 24, 2013 02:00 AM
Title: Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report Abused Children at Risk for Obesity as Adults: StudyMay 24, 2013 02:00 AM
Title: Abused Children at Risk for Obesity as Adults: Study Underactive Thyroid and Heart Failure a Bad Combination: StudyMay 24, 2013 02:00 AM
Title: Underactive Thyroid and Heart Failure a Bad Combination: Study |